129 related articles for article (PubMed ID: 37103089)
1. Evaluation of the Time to Onset and Outcome of Lenalidomide-induced Thrombosis and Embolism Using Spontaneous Reporting Database.
Sato J; Yamamoto N; Kawahara Y; Shimizu T; Uchida M
In Vivo; 2023; 37(3):1246-1252. PubMed ID: 37103089
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database.
Sato J; Eren T; Murata S; Shimizu T; Uchida M
Anticancer Res; 2022 Dec; 42(12):5917-5925. PubMed ID: 36456140
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL; Tinôco JDS; Pascoal PI; Areias LL; Cossi MS; Fernandes MI; Costa IK; Souza L; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013739. PubMed ID: 33502773
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Middleton P; Shepherd E; Gomersall JC
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001689. PubMed ID: 33779986
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
8. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.
Hansson PO; Sörbo J; Eriksson H
Arch Intern Med; 2000 Mar; 160(6):769-74. PubMed ID: 10737276
[TBL] [Abstract][Full Text] [Related]
9. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Perrotta C; Chahla J; Badariotti G; Ramos J
Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
11. Treatment of distal deep vein thrombosis.
Kirkilesis G; Kakkos SK; Bicknell C; Salim S; Kakavia K
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013422. PubMed ID: 32271939
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
13. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.
Roderick P; Ferris G; Wilson K; Halls H; Jackson D; Collins R; Baigent C
Health Technol Assess; 2005 Dec; 9(49):iii-iv, ix-x, 1-78. PubMed ID: 16336844
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolism as the adverse event of combined oral contraceptives in Japan.
Sugiura K; Kobayashi T; Ojima T
Thromb Res; 2015 Dec; 136(6):1110-5. PubMed ID: 26475406
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
Yang X; Brandenburg NA; Freeman J; Salomon ML; Zeldis JB; Knight RD; Bwire R
Clin Drug Investig; 2009; 29(3):161-71. PubMed ID: 19243209
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
17. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
18. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
[TBL] [Abstract][Full Text] [Related]
19. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
20. Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.
Ozawa T; Namkoong H; Takaya R; Takahashi Y; Fukunaga K; Enoki Y; Taguchi K; Kizu J; Matsumoto K; Hasegawa N
BMC Infect Dis; 2022 Jun; 22(1):580. PubMed ID: 35768763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
